Literature DB >> 22848023

De novo microdeletion of 5q14.3 excluding MEF2C in a patient with infantile spasms, microcephaly, and agenesis of the corpus callosum.

Keiko Shimojima1, Akihisa Okumura, Harushi Mori, Shinpei Abe, Mitsuru Ikeno, Toshiaki Shimizu, Toshiyuki Yamamoto.   

Abstract

The 5q14.3 microdeletion syndrome has recently been recognized as a clinical entity manifesting as severe intellectual disability, epilepsy, and brain malformations. Analysis of the shortest region of overlap among patients with this syndrome and subsequent identification of nucleotide alterations in the coding region of myocyte enhancer factor 2C gene (MEF2C) have suggested MEF2C as the gene responsible for the 5q14.3 microdeletion syndrome. We identified a de novo 3.4-Mb deletion of 5q14.3 in a patient with infantile spasms, microcephaly, and brain malformation. The deleted region in the present patient was positional toward the centromere, and MEF2C was not included in the deleted region. However the neurological and dysmorphic features of the present patient resembled those of patients with the 5q14.3 microdeletion syndrome. We consider that a positional effect is the likely explanation for this evidence. To study the precise mechanism of this positional effect, further information is required on patients showing atypical deletions neighboring MEF2C.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22848023     DOI: 10.1002/ajmg.a.35490

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  MEF2C-Related 5q14.3 Microdeletion Syndrome Detected by Array CGH: A Case Report.

Authors:  Jae Sun Shim; Kyunghoon Min; Seung Hoon Lee; Ji Eun Park; Sang Hee Park; MinYoung Kim; Sung Han Shim
Journal:  Ann Rehabil Med       Date:  2015-06-30

2.  Refining the phenotype associated with MEF2C point mutations.

Authors:  Thierry Bienvenu; Bertrand Diebold; Jamel Chelly; Bertrand Isidor
Journal:  Neurogenetics       Date:  2012-09-23       Impact factor: 2.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.